Moving the Industry Forward

LNP Strategy

Building Better RNA Medicines Through Smarter LNP Formulation Strategy

Aula Al Muslim, Ph.D.

Recipharm Advanced Bio

Oligo Analytics

Impurities, Sequence Fidelity, and Structural Variants in Nucleic Acid Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

In Vitro vs. In Vivo Potency Assays: Which Approach Is Best for Biopharmaceutical Product Characterization?

Pharma's Almanac

PAT

Real-Time Insight in Biologic Manufacturing: Why PAT Matters for Commercial Scale-Up

David Alvaro, Ph.D.

Pharma's Almanac

PAT

From Analytical Visibility to Real-Time Control in Biologics Purification

David Alvaro, Ph.D.

Pharma's Almanac

ADCs

Accelerating ADC Analytical Method Development Through Platform Innovation

Jaeook Kim, Ph.D.

Samsung Biologics

Biosimilars

Biosimilars at a Crossroads: Will the FDA’s New Framework Deliver Competition?

David Alvaro, Ph.D.

Pharma's Almanac

Mass Spectrometry

Growing Importance of Mass Spectrometry from Drug Discovery through Commercialization and Life Cycle Management

Stefan Lehnert, Ph.D.; Carsten Kroeger, Dr. rer. nat.

Coriolis Pharma

APM

Raising the Bar in Analytical Excellence: Samsung Biologics’ Approach to Assay Performance Monitoring

Jinwon Choi, Ph.D.; Siyoong Seo; Masany Jung; Soeun Jang

Samsung Biologics

Cell Therapy

Building a Better Cell Therapy CDMO

Kincell Bio

Biologics

HIPRA Biotech Services' End-to-End Biologics Offering

HIPRA Biotech Services

Biotech

Australia: Life Sciences' New Frontier

Mark W. Womack

BioCina